SOUTH EASTON, Mass., Sept. 23 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI" or the "Company") today announced that the Company's pressure cycling technology ("PCT") was highlighted in five separate podium presentations at the Fifth International Conference on High Pressure Bioscience and Biotechnology ("HPBB"), held from September 15-19, 2008 in San Diego, CA. The HPBB Conference was attended by nearly 100 high pressure research scientists from government, academic, and industry laboratories from around the world. PBI was one of several sponsors to support the meeting.
Dr. Nathan Lawrence, Vice President of Marketing for PBI said: "We are very pleased to have been prominently featured at a conference of world class scientists working in applications of high pressure. In addition to two presentations by PBI scientists, three other talks were presented by users of the PCT Sample Preparation System. Dr. Bradford Powell of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) was selected to give an opening scientific presentation entitled "Use of Pressure Cycling Technology (PCT) in Sample Decontamination and Biomolecule Extraction for Analysis of the Anthrax Spore Proteome." In addition, Dr. Daniel Lopez-Ferrer of Pacific Northwest National Laboratories (PNNL) discussed the significant advantages offered by PCT in the study of proteins in his presentation entitled "Application of Pressure for Ultra Fast Protein Digestion in Proteomics." Finally, Dr. Yiping Cao of the Southern California Water Research Project (SCWRP) gave a presentation entitled "Comparison of Pressure Cycling and Bead Beating Technologies for DNA Extraction from Polycarbonate Membranes for Water Quality Analysis." These presentations illustrate the breadth of applications afforded by PCT. We believe that exposure at meetings such as HPBB will help PBI reach its goal of worldwide market leadership in high pressure bioscience and biotechnology."
PBI also announced that it introduced its patent-pending "PCT Shredder" during the HPBB Conference, the third new PCT-dependent product that the Company has released over the past four months. The PCT Shredder was designed to help research scientists safely, rapidly, and conveniently disrupt very tough samples -- such as ticks, muscle, and seeds -- that require homogenization prior to PCT or other sample preparation methods.
Mr. Richard T. Schumacher, Founder, President, and CEO of PBI commented: "Extremely tough samples often require a pre-processing step as part of the sample preparation process. The PCT Shredder was designed to rapidly and safely process a wide range of such samples. It uses the same PULSE Tube as the PCT Sample Preparation System (PCT SPS). This allows scientists to homogenize tough samples in the PCT Shredder followed directly by extraction with the PCT SPS, but without the need to transfer the sample into a second processing container between steps. This is unique to the sample preparation market. We believe this reduction in sample handling should result in a decrease in cost for the user and a potential reduction in sample loss and laboratory errors. We further believe that the advantages of the PCT Shredder will help us significantly in our goal to achieve greater market acceptance and penetration, and leadership in the worldwide sample preparation field."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.
Forward Looking Statements
Statements contained in this press release regarding the Company's
intentions, hopes, beliefs, expectations, or predictions of the future are
"forward-looking'' statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward looking statements include
statements regarding the expected advantages of the Company's PCT Shredder,
alone or in combination with the Company's Pressure Cycling Technology
Sample Preparation System (PCT SPS), over other currently available sample
preparation methods for processing ticks, muscle, seeds, and other very
tough samples; the PCT Shredder method is more cost effective, less
time-consuming, and less problematic than competitive methods; the breadth
of applications afforded by PCT; that exposure at meetings such as HPBB
will help PBI reach its goal of worldwide market leadership in high
pressure bioscience and biotechnology; the advantages of PCT SPS over
competitive processes; and the Company's goal of gaining greater market
acceptance and penetration, and leadership in the worldwide sample
preparation field. These statements are based upon the Company's current
expectations, forecasts, and assumptions that are subject to risks,
uncertainties, and other factors that could cause actual outcomes and
results to differ materially from those indicated by these forward-looking
statements. These risks, uncertainties, and other factors include, but are
not limited to: unforeseen technological difficulties that the Company may
encounter in the development of the PCT technology and products using the
PCT technology; due to such unforeseen technical difficulties, or
marketing, sales, and distribution difficulties, the PCT Shredder and the
PCT Sample Preparation System may not be adopted by the scientific
community as an accepted method of bio-molecule extraction; due to the
Company's limited financial resources, if the Company is unable to secure
financing, it will be forced to substantially curtail its planned
operations which will limit the Company's ability to achieve market
acceptance and penetration; and the other risks and uncertainties discussed
under the heading "Risk Factors" in the Company's Annual Report on Form
10-K for the year ended December 31, 2007 and other reports filed by the
Company from time to time with the SEC. The Company undertakes no
obligation to update any of the information included in this release,
except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
Richard T. Schumacher, President & CEO
Edward H. Myles, Sr. Vice President of Finance & CFO
(508) 230-1828 (T)
Pressure BioSciences, Inc.
|SOURCE Pressure BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved